ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb is shelling out $35 million up front and up to $430 million in milestones for access to IPH2102, a monoclonal antibody being developed by Innate Pharma. IPH2102 taps into a cancer patient’s own immune system by blocking the interaction between killer-cell immunoglobulin-like receptors and their ligands. Blocking the receptors activates natural killer cells that in turn destroy tumor cells. The drug is now in Phase I cancer trials. France-based Innate will continue to develop it through a Phase II trial for acute myeloid leukemia.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter